Myelodysplastic Syndrome Clinical Trial
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
Summary
The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.
View Eligibility Criteria
Eligibility Criteria
Inclusion Criteria:
Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan (RA101495) PNH study
Evidence of ongoing clinical benefit in the opinion of the Investigator
Exclusion criteria:
History of meningococcal disease
Current systemic infection or suspicion of active bacterial infection
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There are 2 Locations for this study
See Locations Near You
Investigative Site 4
Los Angeles California, 90033, United States
Los Angeles California, 90033, United States
Investigative Site 19
Dallas Texas, 75390, United States
Dallas Texas, 75390, United States
Investigative Site 3
Gosford , , Australia
Gosford , , Australia
Investigative Site 5
Melbourne , , Australia
Melbourne , , Australia
Investigative Site 10
Toronto , , Canada
Toronto , , Canada
Investigative Site 14
Helsinki , , Finland
Helsinki , , Finland
Investigative Site 9
Ulm , , Germany
Ulm , , Germany
Investigative Site 17
Budapest , , Hungary
Budapest , , Hungary
Investigative Site 13
Christchurch , , New Zealand
Christchurch , , New Zealand
Investigative Site 12
Hamilton , , New Zealand
Hamilton , , New Zealand
Investigative Site 6
Leeds , , United Kingdom
Leeds , , United Kingdom
Investigative Site 7
London , , United Kingdom
London , , United Kingdom
How clear is this clinincal trial information?